Skip to main content
Home > BC Innovations > Cover Story

Chronological Index of : Cover Story

 Current Issue
  • Cancer's Phoenix

    A safer IL-2-based immunotherapy without compromised efficacy

    Courier Therapeutics may have solved the longstanding problem of how to avoid the lethal side effects of IL-2 cancer immunotherapy without compromising efficacy.

    Published on 10/27/2016
  • Figure: Aim intermediate

    Cancer's Phoenix Targets & Mechanisms Aim intermediate To avoid dose-limiting toxicities associated with recombinant IL-2, researchers at Washington University in St. Louis have created a fusion protein that …

    Published on 10/27/2016
  • Figure: Check This Out

    Cancer's Phoenix Targets & Mechanisms Check This Out Therapeutic response rates for metastatic renal cell carcinoma (RCC) patients treated with high-dose IL-2 or anti-PD1 antibody therapies, broken down by complete…

    Published on 10/27/2016
  • Table: BioCentury Product Profile

    Cancer's Phoenix Targets & Mechanisms BioCentury Product Profile BioCentury Product Profile INNOVATION STAGE Product A fusion protein comprising a mutant form of IL-2 with diminished CD25 binding, linked to the …

    Published on 10/27/2016
  • Table: Everything old is new again

    Cancer's Phoenix Targets & Mechanisms Everything old is new again IL-2-based therapeutics in clinical and preclinical development. At least seven products containing a form of IL-2 are in clinical development, and …

    Published on 10/27/2016
  • Figure: Chaperoned pairing

    Chaperoning the DJ Product R&D Chaperoned pairing Cantabio Pharmaceuticals Inc. (OTCQB:CTBO) is developing pharmacological chaperones to prevent protein misfolding in neurological diseases. The company's lead …

    Published on 10/20/2016
  • Table: BioCentury Product Profile

    Chaperoning the DJ Product R&D BioCentury Product Profile BioCentury Product Profile INNOVATION STAGE Product A compound that stabilizes the dimeric form of DJ-1, a chaperone protein and oxidative stress sensor…

    Published on 10/20/2016
  • Chaperoning the DJ

    How Cantabio is using chaperones to rein in multiple PD pathways

    By stabilizing the chaperone and oxidative stress sensor DJ-1, Cantabio is aiming to block multiple PD pathways with a single compound.

    Published on 10/20/2016
  • Exosomes in the zone

    Academia and industry agree that exosomes are ready for prime time

    The rise in exosome knowledge has the field poised to deliver a possibly transformational technology for diagnostics, with therapeutic applications on their trail.

    Published on 10/13/2016
  • Figure: Exosome publications

    Exosomes in the zone Strategy Exosome publications The publication of exosome-related papers has risen by an order of magnitude since 2006, and the totals for 2016 through Oct. 11 have already surpassed 2015 totals…

    Published on 10/13/2016
  • Table: Companies chasing exosomes

    Exosomes in the zone Strategy Companies chasing exosomes At least 12 companies are pursuing therapeutics or diagnostics that utilize exosomes, including at least seven whose primary focus is exosome-based …

    Published on 10/13/2016
  • Table: Exosomes in fashion

    Exosomes in the zone Strategy Exosomes in fashion At least three new companies have been founded in the last two years based on exosome technology, and a fourth company, founded earlier, raised early stage …

    Published on 10/13/2016
  • Local sensitivity

    How Cell Design rewires T cell therapies for local action in multiple diseases

    Cell Design is rewiring cells for local delivery of therapeutics, using synthetic receptors that respond to endogenous cues in the tissue or tumor microenvironment.

    Published on 10/6/2016
  • Box: CAR factories

    Local sensitivity Product R&D CAR factories While Cell Design Labs Inc. created a system for cell therapies to produce proteins in vivo in response to endogenous cues, a team from Memorial Sloan Kettering Cancer …

    Published on 10/6/2016
  • Box: Taking it up a notch

    Local sensitivity Product R&D Taking it up a notch In a study in Cell, a University of California San Francisco team showed how its synthetic Notch (synNotch) technology turns T cells into "smart" agents that …

    Published on 10/6/2016
  • Figure: Taking it up a notch

    Local sensitivity Product R&D Taking it up a notch In a study in Cell, a University of California San Francisco team showed how its synthetic Notch (synNotch) technology turns T cells into "smart" agents that …

    Published on 10/6/2016
  • Table: BioCentury Product Profile

    Local sensitivity Product R&D BioCentury Product Profile BioCentury Product Profile INNOVATION STAGE Product Synthetic Notch (synNotch) receptor circuits for T cell therapies Throttle Switch for chimeric …

    Published on 10/6/2016
  • Safety Factor

    How Pfizer aims to compete in the Factor XIa space

    Pfizer and UCSF researchers believe their anti-Factor XIa mAb can serve some subpopulations left behind by the safety gaps of Factor Xa inhibitors.

    Published on 9/29/2016
  • Figure: Counting factors

    Safety Factor Product R&D Counting factors In a Science Translational Medicine study, Pfizer Inc. (NYSE:PFE) and University of California San Francisco researchers showed the anti-clotting effects of their anti-…

    Published on 9/29/2016
  • Table: BioCentury Product Profile

    Safety Factor Product R&D BioCentury Product Profile BioCentury Product Profile INNOVATION STAGE Product Factor XIa-blocking mAb, plus antidote reversal agent for safety Concept Blocking Factor XIa to prevent …

    Published on 9/29/2016
  • In the CRISPR tea leaves

    How deal flow is beginning to reveal CRISPR company strategies

    The deal flow by foundational CRISPR companies is providing clues into what they are prioritizing to take into the clinic.

    Published on 9/22/2016
  • Figure: 2 patents, 3 inventors, 4 companies

    In the CRISPR tea leaves Strategy 2 patents, 3 inventors, 4 companies The foundational CRISPR patents have undergone a series of licensing transactions, resulting in four therapeutically focused companies with …

    Published on 9/22/2016
  • Table: CRISPR collaborations

    In the CRISPR tea leaves Strategy CRISPR collaborations Select licensing and collaboration deals made by the four foundational CRISPR companies. Since December 2014, at least 17 partnerships or licensing deals were…

    Published on 9/22/2016
  • Table: γδ Companies

    Enter GammaDelta Product R&D γδ Companies Select companies developing γδ T cell-based cell therapies for cancer. Source: BCIQ: BioCentury Online Intelligence; company websites Company Product(s) Description T …

    Published on 9/15/2016
  • Table: BioCentury Product Profile

    Enter GammaDelta Product R&D BioCentury Product Profile BIOCENTURY PRODUCT PROFILE INNOVATION STAGE Product γδ T cell therapy Concept Cell therapy for cancer using patient- or donor-sourced tissue-resident γδ …

    Published on 9/15/2016

< Previous   1  2  3  4  5  6  Next >

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993